Translating Epoetin Research Into Practice: The Role Of Government And The Use Of Scientific Evidence

Spending for epoetin is Medicare’s single largest drug expenditure. We chronicle the evolution of epoetin policy based on a lack of well-designed post–Food and Drug Administration approval studies demonstrating clinical benefit; congressional/federal agency reliance on clinical practice guidelines that might have misinterpreted evidence supporting causality; and the premature translation of research into practice and policy. Were the right choices made? Epoetin showcases the risk and benefit conundrum created when evidentiary standards are relaxed. Our review concludes with broad-based policy recommendations for the newly implemented Medicare Part D program.